Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elliot Stieglitz

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Cell Reports. Medicine|November 22, 2023
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AMLBogdan Popescu, Carlos Stahlhut, Theodore C Tarver, et al.
Genes, Chromosomes & Cancer|May 19, 2019
Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in childrenAdam J de Smith, Geneviève Lavoie, Kyle M Walsh, et al.
Cancers|February 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) ConsortiumAnupam Verma, Yueh-Yun Chi, Jemily Malvar, et al.
Blood|November 15, 2014
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemiaElliot Stieglitz, Camille B Troup, Laura C Gelston, et al.
Pediatric Blood & Cancer|March 13, 2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group studyChristopher C Dvorak, Prakash Satwani, Elliot Stieglitz, et al.
JCO Precision Oncology|December 7, 2020
Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC SignatureAnya Levinson, Alex G Lee, Henry J Martell, et al.
Blood|October 27, 2025
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AMLBogdan Popescu, Matthew F Jones, Madison Piao, et al.
Blood Advances|September 22, 2021
Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasmOriana Miltiadous, Kseniya Petrova-Drus, Shipra Kaicker, et al.
Blood Neoplasia|August 27, 2025
Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletionsTamara Westover, Michael P Walsh, Sherif Abdelhamed, et al.
Cancer Discovery|March 17, 2021
Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>-Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALLMatthew A Nix, Kamal Mandal, Huimin Geng, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Cell Reports. Medicine|November 22, 2023
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AMLBogdan Popescu, Carlos Stahlhut, Theodore C Tarver, et al.
Genes, Chromosomes & Cancer|May 19, 2019
Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in childrenAdam J de Smith, Geneviève Lavoie, Kyle M Walsh, et al.
Cancers|February 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) ConsortiumAnupam Verma, Yueh-Yun Chi, Jemily Malvar, et al.
Blood|November 15, 2014
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemiaElliot Stieglitz, Camille B Troup, Laura C Gelston, et al.
Pediatric Blood & Cancer|March 13, 2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group studyChristopher C Dvorak, Prakash Satwani, Elliot Stieglitz, et al.
JCO Precision Oncology|December 7, 2020
Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC SignatureAnya Levinson, Alex G Lee, Henry J Martell, et al.
Blood|October 27, 2025
Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AMLBogdan Popescu, Matthew F Jones, Madison Piao, et al.
Blood Advances|September 22, 2021
Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasmOriana Miltiadous, Kseniya Petrova-Drus, Shipra Kaicker, et al.
Blood Neoplasia|August 27, 2025
Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletionsTamara Westover, Michael P Walsh, Sherif Abdelhamed, et al.
Cancer Discovery|March 17, 2021
Surface Proteomics Reveals CD72 as a Target for <i>In Vitro</i>-Evolved Nanobody-Based CAR-T Cells in <i>KMT2A/MLL1</i>-Rearranged B-ALLMatthew A Nix, Kamal Mandal, Huimin Geng, et al.
Pageof 9